Introduction: Angiotensin converting enzyme inhibitors are commonly prescribed medications
| I N TR ODU C TI ON
Hypoplastic left heart syndrome (HLHS) describes a set of congenital heart defects that adversely affects systemic blood flow. 1 
HLHS and its
variants have a prevalence of 1.3 to 3.2 per 10 000 live births. [2] [3] [4] [5] In the absence of anatomical intervention, HLHS is almost uniformly lethal in the neonatal period. Survival for most affected neonates is contingent on receiving a series of surgical or combined surgical and interventional catheterization procedures in the first months of life. A variation of the Norwood procedure is the first definitive palliative procedure in the series. The Norwood procedure, and its variations, create a reliable source of blood flow to the body, eliminate any blockage to flow due to an abnormal atrial septum, and create a reliable source of pulmonary blood flow. Irrespective of which variation of the first-stage procedure is used to achieve these goals, balance between blood flow to the body (including coronary blood flow) and to the lungs is tenuous.
Establishing a connection between the superior vena cava and the pulmonary artery, and removing the path for pulmonary blood flow that was created during the first-stage, is the most common secondstage procedure (Glenn procedure). 6 While infants following the second-stage palliation usually remain somewhat medically fragile, many of the risks inherent in first-stage physiology are mitigated.
Although the thirty-day survival after the Norwood procedure has increased over the past three decades, 6, 7 the interstage period, the time between the Norwood and the Glenn procedures, remains one of the most critical times in the management of infants with single ventricle defects, with mortality ranging from 4 to 15% depending on the surgical center. 6 Risk factors for interstage death include poor somatic growth, comorbid conditions (e.g., gastroenteritis, infection, fever), arrhythmias, and residual or recurrent anatomic lesions of the heart. [6] [7] [8] Angiotensin converting enzyme inhibitors (ACE-I) are one of the most common outpatient medications used after the Norwood procedure, with 38% to 73% of neonates receiving these medications.
9,10
The reason for use of ACE-I therapy is to reduce cardiac afterload and by doing so increasing cardiac output to the systemic circulation. ACE-I have FDA approved indications for treatment of high blood pressure, heart failure, left ventricular dysfunction, and diabetic nephropathy. 11, 12 The safety and efficacy of ACE-I therapy in neonates, who are more prone to hemodynamic and renal side effects of ACE-I therapy than older children and adults, have not been established. 13, 14 There is considerable variability in the use of ACE-I therapy in neonates and young infants with HLHS. ACE-I therapy is primarily based on empirical data 10 and evidence of beneficial effects of ACE-I therapy in children with heart failure. 15 Despite the paucity of evidence supporting ACE-I therapy in neonates and infants with HLHS, 10, 16 receive the treatment will be biased by the severity of the disease at the time treatment is begun.
The purpose of this study was to evaluate, in infants with HLHS, the relationship between use of ACE-I immediately after the Norwood procedure and interstage failure using a technique, propensity score matched cohorts, which addresses confounding by indication. 18 We defined interstage failure as death during the interstage period, heart transplantation, or not a being candidate for the second-stage procedure.
We tested the hypothesis that infants who were prescribed ACE-I at discharge from the Norwood procedure had decreased incidence of interstage failure compared to infants who were not discharged on ACE-I therapy. 
| Study population
Infants who had qualifying single ventricle defects, received the Norwood procedure, and were discharged from the hospital with tentative plans to have the second-stage surgery were included in the NPC-QIC.
Children were enrolled in the registry with the consent of their parents or guardians who signed an informed consent. Children were not eligible to participate in the registry if they died before discharge from the Norwood procedure or if they were hospitalized during the entire interstage period.
| Primary outcome variable
The primary outcome of interest, interstage failure, was defined as death during the interstage period, heart transplantation, or not a being candidate for the second-stage procedure. Interstage failure was modeled as a dichotomous variable (failure or success).
| Primary exposure variable
The primary exposure variable was ACE-I use at discharge from the Norwood, defined as either prescribed or not prescribed. ACE-I medications included in this study were captopril, enalapril, and lisinopril.
| Statistical analyses
Student's t-tests and Pearson chi-square tests were used to compare characteristics of subjects receiving and not receiving ACE-I therapy.
We used logistic regression to evaluate the relationship between ACE-I therapy and interstage failure. We ran three models. The first model was not adjusted for any covariates nor were propensity scores used in the analyses. All subjects (n 5 1 487) for whom outcome and ACE-I usage (or nonusage) was known were included. The second model (Model 2, n 5 1 446) included all subjects for whom a propensity score could be computed (i.e. the subjects had complete data for all the variables included in the propensity score), but the propensity scores were not considered in the analysis. Model 2, like Model 1 was not adjusted for any covariates. The third model (Model 3, n 5 1 104), included subjects who received ACE-I therapy and were matched (1:1 matching, as described below) to a subject who did not receive ACE-I therapy based on the subject's propensity (ie, probability) of receiving ACE-I therapy.
Model 3, run as a conditional logistic regression, assessed the relationship between ACE-I therapy and interstage failure in the propensityscore matched cohort adjusted for those covariates which, despite the matching, remained unbalanced between subjects who did and did not receive ACE-I therapy. A covariate was considered unbalanced when the absolute value of the between group standardized difference was 0.1. 18 Independent variables included in the model based on imbalance were primary cardiac diagnosis and type of operative procedure.
Based on a review of the literature 21 and consideration of clinical relevance we identified nine variables that we included in the computation of our propensity scores, the conditional probability of receiving ACE-I given the neonates' baseline health status. Variables used to compute the propensity scores included the subject's sex, race, primary cardiac diagnosis, preoperative and postoperative risk factors that were associated with either receiving ACE-I therapy or having an interstage failure, presence of renal dysfunction, major organ system abnormalities, type of operative procedure, and need for cardiac reoperation.
Race was characterized as white, African American and other. Primary cardiac diagnosis included aortic atresia with mitral atresia, aortic atresia with mitral stenosis, aortic stenosis with mitral stenosis, and other. The need for reoperation was a dichotomous variable indicating whether the patient needed to undergo an additional surgery between the Norwood and discharge.
Patients discharged on ACE-I were matched (1:1) without replacement on propensity scores to patients who were not discharged on ACE-I. Matching was conducted using a caliper of width equal to 0.1 standard deviation of the estimated propensity scores.
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A two-tailed P < 0.05 was considered statistically significant. Data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
| RE S U L TS
One thousand five hundred one patients were eligible to participate in this study ( Figure 1 ). We excluded 14 participants because they were lost to follow-up or had biventricular repairs. Patients with missing covariates (n 5 41) were not considered for propensity score matching.
There were no differences in sex, race, primary cardiac diagnosis, the presence of pre-and postoperative risk factors, renal problems, and major organ system abnormalities between participants with complete data and those with missing covariates (data not shown). Ninety-seven percent (552/569) of patients discharged on ACE-I were matched to patients who were not discharged on ACE-I achieving a total of 1 104
participants for the matched analysis.
| Sample characteristics
The mean age of the neonates at the time of the Norwood procedure was 10.9 6 71.1 days (mean 6 SD) and 46.0 6 75.4 days at discharge.
The majority of our subjects were male (61%), White (75%), did not have preoperative risk factors (87%), postoperative risk factors (92%), renal problems (88%) or major organ system abnormalities (92%), and did not need a reoperation (80%).
| Comparison of patients who did and did not received ACE-I
Among the 1 446 subjects who had complete information on ACE-I usage, outcome, and covariates (Model 2), those discharged on ACE-I were more likely to have pre-and postoperative risk factors, renal problems, major organ system abnormalities, and Norwood with BlalockTaussig shunt compared to patients not discharged on ACE-I (Table 1) .
After propensity score matching (Model 3, n 5 1 104), treatment groups were comparable on almost all covariates except the presence of primary cardiac diagnosis (|d|50.12) and type of operative procedure (|d|5 0.13) ( Table 2 ). In the matched cohort, patients discharged on ACE-I were slightly more likely to receive the diagnosis of aortic stenosis with mitral stenosis and less likely to have undergone hybrid Norwood. Primary cardiac diagnosis and type of operative procedure were therefore included in the conditional logistic regression model.
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| Relationship between ACE-I and interstage failure
In our original sample (Model 1), 39% of the patients were prescribed ACE-I at discharge from the Norwood, and 11% failed during the interstage period. Patients discharged on ACE-I were significantly more likely to fail during the interstage period compared to patients not discharged on ACE-I (odds ratio 5 1.44; 95%CI: 1.04, 1.99; P 5 0.03) ( Table 3) . After excluding patients for whom a propensity score could not be computed 
| D I SCUSSION
This study does not support our primary hypothesis that infants discharged on ACE-I would have decreased incidence of interstage failure compared to infants not discharged on ACE-I therapy. Our initial model 
| ACE-I in children with single ventricle defects
Although use of ACE-I therapy has been associated with improved health in older children and adults with heart failure, 15 the use of enalapril has not shown beneficial effects in treating ventricular dysfunction in single ventricle defects. 23 In a randomized trial of children aged 45 days or younger with single ventricle defects, there was no difference in somatic growth, ventricular function, or heart failure severity among children who received enalapril during the first year of life and those who did not. 23 In a study of the use of any single ACE-I drug (enalapril, lisinopril or captopril) in children with single ventricle defects, ACE-I therapy did not improve interstage survival or weight gain. failure may be due to noncardiac causes such as feeding difficulties, genetic problems, and comorbidities 23 and so would not be affected by ACE-I therapy. Another explanation may be the physiologic action of ACE-I. Because ACE-I decrease blood pressure, 24 the therapy may compromise coronary artery filling, which may interfere with blood flow to the myocardium, resulting in myocardial ischemia, impaired ventricular function, and arrhythmias.
Although there is no evidence in the literature, nor from our study, that supports the use of ACE-I therapy during the interstage period in children with single ventricle defects, a high proportion of this population is discharged on this therapy (39% in our study). Physicians may believe that ACE-I therapy will be helpful based on the demonstrated salutary effect ACE-I therapy has in children (1 month-14 years) with heart failure; ACE-I drugs lower aortic pressure, systemic vascular resistance, and atrial pressure in these children. 15 ACE-I therapy has also been associated with reduced ventricular dilation, which improves the prognosis in patients with heart failure. 25, 26 The differential effects of ACE-I in children with heart failure when compared with infants with single ventricle defects may suggest age-related differences in pharmacodynamics or end-organ response.
| Use of propensity-score method
Propensity score matching was used to reduce the possibility of confounding by indication. This type of confounding is usually a concern in observational pharmaco-epidemiologic studies when individuals who are prescribed a medication are inherently different from those who do not take the medication. In our sample, infants who were discharged 
| Strengths and limitations
This study has several limitations. Our study is based on data collected with the aim of improving quality of care, and not specifically to address the question that we explore. The conditions reported in medical records and used in the NPC-QIC registry were not corroborated, so nondifferential misclassification cannot be ruled out. Further our study is not a randomized clinical trial. It is possible that there was selection bias in the patients who participated in the NPC-QIC registry.
Some infants who were included in the registry could not be included in our propensity-score analyses (Model 3) due to missing data.
Although there were no differences in most of the baseline covariates between participants with complete data and those with missing covariates, we saw differences in the type of operative procedure and the need for reoperation. Children with missing information were more likely to undergo reoperation (34% vs. 20%; P 5 0.04) and 'other' type of operative procedure (24% vs. 7%; P < 0.01). In addition, our analyses did not account for various combinations of drugs, medication changes or discontinuation of ACE-I during the interstage period. As with any observational study, the possibility of residual confounding still exists.
Our study has a number of strengths. First, to our knowledge this is the first study to examine the association between ACE-I therapy and interstage failure in children with single ventricle defects. We are unaware of any prior studies that evaluated interstage failure as a composite outcome defined as death, heart transplantation or not being a candidate for the second operation. Second, despite the observational nature of our study, we used propensity scores to reduce the possibility of confounding by indication. Third, the sample size was large compared to prior studies investigating the effects of ACE-I therapy in children with single ventricle.
| C ONC LUSI ON
ACE-I therapy did not demonstrate beneficial effect in infants with HLHS during the interstage period; in fact, there is a suggestion that ACE-I therapy may be detrimental. Further investigations, preferably
properly powered randomized studies, are warranted to evaluate the effect of ACE-I therapy on interstage failure.
